Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for Sept. 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss recent advancements and challenges, offering Silo an opportunity to engage with key opinion leaders as it advances its lead candidate, SPC-15, a nose-to-brain therapy for post-traumatic stress disorder (PTSD).
The company's participation comes on the heels of promising preclinical data for SPC-15. The formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality through nine months, with six-month accelerated stability data consistent and aligned with long-term stability results. These findings are critical for regulatory submissions and eventual commercialization, as they demonstrate the product's robustness and reliability.
Eric Weisblum, CEO of Silo Pharma, emphasized the significance of the forum in advancing the company's research. "The IPAC-RS forum is an ideal venue to share insights and collaborate with leaders in nasal drug delivery," he said. "We are committed to developing innovative solutions for underserved conditions, and SPC-15's progress highlights our dedication to bringing novel treatments to patients."
Silo Pharma's therapeutic focus extends beyond PTSD, with a pipeline that includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's research is conducted in collaboration with leading universities and laboratories, ensuring a strong scientific foundation.
The nasal delivery route is particularly attractive for central nervous system (CNS) drugs because it bypasses the blood-brain barrier, allowing for direct transport to the brain. This approach could enhance efficacy and reduce systemic side effects, addressing a significant challenge in CNS drug development.
For more information about Silo Pharma, visit the company's website at silopharma.com. To view the full press release, visit https://ibn.fm/Dy4qf.
Investors interested in the latest news and updates from Silo Pharma can access the company's newsroom at https://ibn.fm/SILO.
